Synchron is a pioneering brain-computer interface company aiming to help paralyzed patients regain communication and mobility. With innovative Stentrode technology and support from high-profile investors like Jeff Bezos and Bill Gates, Synchron has drawn lots of attention in the BCI field. As Synchron plans to go public in 2023, many investors are interested in its IPO prospects and looking for tips on how to invest in this emerging medtech innovator. Here are some key information and suggestions regarding investing in Synchron.
Synchron Stentrode enables minimally invasive BCI implantation
Synchron’s flagship product Stentrode allows endovascular implantation of electrodes to record brain signals for BCI applications. This minimally invasive approach avoids open brain surgery and its risks. Stentrode has been successfully implanted in four human subjects in an early feasibility study, enabling them to control digital devices hands-free via thought. Synchron is now conducting further trials to gather safety and efficacy data for regulatory approval.
Strong leadership and high-profile investor backing
Synchron was founded in 2012 by CEO Thomas Oxley, a neurointerventionalist who pioneered the Stentrode technology. The company is based in California and Australia. Synchron has raised over $68 million funding so far from investors including Jeff Bezos’ Bezos Expeditions, The Kraft Group, Horizons Ventures, Blackbird Ventures, etc. The confidence of these top-tier VCs speaks volumes about Synchron’s potential.
Synchron aims for 2023 IPO after new funding round
In August 2022, Synchron announced it has secured commitments totaling $75 million in a Series C financing round, led by VC firm ARCH Venture Partners. The fresh capital will help Synchron advance its clinical programs and scale up operations for commercialization. Synchron is expected to pursue an IPO in 2023 after this funding round, which will allow public investment into the company.
Key strategies for investing in Synchron
For investors interested in the promising BCI field and Synchron specifically, some suggestions are: closely track Synchron’s IPO plans and financials pre-IPO; be aware of the risks inherent in investing in emerging biotech firms; consider investing via healthcare/biotech funds focused on neurotech rather than direct stock purchase to mitigate risks; have a long-term investment horizon as commercialization and adoption of novel medical devices takes time.
The future is bright for innovative neurotech like Synchron
Synchron’s minimally invasive Stentrode has the potential to profoundly transform the lives of paralyzed patients by restoring communication and mobility via thought control. Synchron’s progress has been impressive given the highly complex nature of BCIs. With solid technical fundamentals and strong leadership/funding support, Synchron is well-positioned to be a frontrunner in the fast-advancing and impactful neurotechnology space. For investors, Synchron presents an exciting opportunity to participate in this medtech revolution early on.
In summary, Synchron’s innovative Stentrode BCI technology, proven early feasibility, and planned 2023 IPO make it an emerging neurotech firm attractive for investors. Tracking Synchron’s IPO plans, leveraging healthcare-focused funds, and maintaining a long-term investment vision can help investors capitalize on this opportunity.